Skip Navigation LinksHome > February 25, 1999 - Volume 13 - Issue 3 > Maternal viral load and timing of mother-to-child HIV transm...
AIDS:
Epidemiology and Social: Original Papers

Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand

Mock, Philip A.*; Shaffer, Nathan*†; Bhadrakom, Chaiporn‡; Siriwasin, Wimol§; Chotpitayasunondh, TaweeII; Chearskul, Sanay‡; Young, Nancy L.*†; Roongpisuthipong, Anuvat‡; Chinayon, Pratharn§; Kalish, Marcia L.†; Parekh, Bharat†; Mastro, Timothy D.*†; for the Bangkok Collaborative Perinatal HIV Transmission Study Group

Free Access
Article Outline
Collapse Box

Author Information

From the *HIV/AIDS Collaboration, Nonthaburi, Thailand, the Centers for Disease Control and Prevention, Atlanta, GA, USA, the Faculty of Medicine Siriraj Hospital, Mahidol University, §Rajavithi Hospital, Department of Medical Services, Ministry of Public Health (MOPH), and ||the Children‚s Hospital, Department of Medical Services, MOPH, Bangkok, Thailand.

Sponsorship: This work was supported by the Centers for Disease Control and Prevention, Atlanta, GA, USA, through the HIV/AIDS Collaboration, a joint activity of the Ministry of Public Health, Thailand, and the US Centers for Disease Control and Prevention.

Requests for reprints to: N. Shaffer, Centers for Disease Control and Prevention (MS E-50), 1600 Clifton Rd, Atlanta, GA 30333, USA.

Note: The use of trade names is for identification only and does not imply endorsement by the Public Health Service of the US Department of Health and Human Services.

Date of receipt: 15 June 1998; revised: 20 October 1998; accepted: 30 October 1998.

Collapse Box

Abstract

Objectives: To determine the proportion of HIV-1-infected infants infected in utero and intrapartum, the relationship between transmission risk factors and time of transmission, and the population-attributable fractions for maternal viral load.

Design: Prospective cohort study of 218 formula-fed infants of HIV-1-infected untreated mothers with known infection outcome and a birth HIV-1-positive DNA PCR test result.

Methods: Transmission in utero was presumed to have occurred if the birth sample (within 72 h of birth) was HIV-1-positive by PCR; intrapartum transmission was presumed if the birth sample tested negative and a later sample was HIV-1-positive. Two comparisons were carried out for selected risk factors for mother-to-child transmission: infants infected in utero versus all infants with a HIV-1-negative birth PCR test result, and infants infected intrapartum versus uninfected infants.

Results: Of 49 infected infants with an HIV-1 birth PCR result, 12 (24.5%) [95% confidence interval (CI), 14 -38] were presumed to have been infected in utero and 37 (75.5%) were presumed to have been infected intrapartum. The estimated absolute overall transmission rate was 22.5%; this comprised 5.5% (95% CI, 3-9) in utero transmission and 18% (95% CI, 13-24) intrapartum transmission. Intrapartum transmission accounted for 75.5% of infections. High maternal HIV-1 viral load (> median) was a strong risk factor for both in utero [adjusted odds ratio (AOR) 5.8 (95% CI, 1.4-38.8] and intrapartum transmission (AOR, 4.4; 95% CI, 1.9-11.2). Low birth-weight was associated with in utero transmission, whereas low maternal natural killer cell and CD4+ T-lymphocyte percentages were associated with intrapartum transmission. The population-attributable fraction for intrapartum transmission associated with viral load >10000 copies/ml was 69%.

Conclusions: Our results provide further evidence that most perinatal HIV-1 transmission occurs during labor and delivery, and that risk factors may differ according to time of transmission. Interventions to reduce maternal viral load should be effective in reducing both in utero and intrapartum transmission.

Back to Top | Article Outline

Introduction

Global rates of mother-to-child HIV-1 transmission are heterogenous; estimates range from 14 to 48% [1]. In non-breastfeeding populations the risk of perinatal HIV transmission is most commonly 15-25% [1-3]. The variation in observed rates may be due to differences in risk factors or to viral characteristics in specific populations, and also to differences in timing of transmission. Although many factors have been associated with an overall increased risk of perinatal HIV transmission including increased maternal viral load, low CD4+ T-lymphocyte counts, decreased maternal cell-mediated immunity, vaginal delivery, prolonged rupture of membranes, prematurity, low birth-weight, and prolonged labor [1,4], risk factors according to time of transmission have not been well characterized.

In the absence of breastfeeding, perinatal HIV transmission can occur either in utero or intrapartum. It has been proposed that among non-breastfed infants, in utero and intrapartum transmission can be distinguished based on early infant HIV-1 DNA PCR or viral culture results [5]. According to this widely used hypothesis, a positive virological result from a blood sample obtained within 48 h of birth indicates presumptive in utero transmission, whereas an initial negative result (within 1 week of birth) followed by a positive result indicates intrapartum transmission. With some modifications of the time-frame for positive results, this definition has been adopted by several investigators [6-12] who have estimated the relative amount of intrapartum transmission to be in the range 62-75% [6-9,11,13]. Determination of the relative contributions of presumed in utero and intrapartum transmission, and an understanding of risk factors specific for time of transmission, is important for the design and interpretation of interventions to reduce perinatal transmission, especially strategies targeting late pregnancy.

Although the mechanisms of in utero and intrapartum transmission are not well understood, it has been suggested that risk factors for in utero transmission probably include maternal factors such as high viral load, low CD4+ T-lymphocyte count and impaired cell- mediated immunity [4]. Maternal viral load, by direct contact with blood or secretions, and immunological factors might also be associated with intrapartum transmission. Theoretically, obstetric factors should be associated with intrapartum transmission and one study found duration of ruptured membranes to be of significance [7]. However, maternal viral load, which may be the most important determinant of transmission, has not been investigated in relation to timing of transmission.

We have separately reported the overall findings on transmission rate and risk factors in a non-breastfeeding perinatal cohort with HIV-1 subtype E infection [14,15]. Maternal viral load was the strongest risk factor for transmission, and gestational age, mode of delivery and maternal natural killer (NK) cell percentage were independent predictors of transmission also. In the current analysis, we estimate the relative and absolute rates of in utero and intrapartum transmission, assess whether maternal and delivery risk factors for perinatal transmission are related to time of transmission, and estimate the population-attributable fraction for maternal viral load, by time of transmission.

Back to Top | Article Outline

Methods

Study population

The Bangkok Collaborative Perinatal HIV Transmission Study recruited HIV-infected pregnant women (first and second 2nd trimesters) from two large Bangkok hospitals during 1992-1994 to participate in a prospective cohort study [16]. Specific counseling was given to avoid breastfeeding, in accord with Thai national guidelines for HIV-positive women. A detailed description of the study methodology and the main findings of the overall transmission rate and risk factors have been reported previously [14,15]. The study was approved by the Ethical Review of Research Committee, Ministry of Public Health, Bangkok, Thailand and by the Institutional Review Board, CDC, Atlanta, USA.

Back to Top | Article Outline
Laboratory testing

Maternal enrollment sera and sequential child plasma samples were tested to confirm HIV antibody status with the Genetic Systems HIV-1/HIV-2 EIA (Genetic Systems, Redwood, WA, USA) and the Novapath HIV-1 Immunoblot (BioRad Laboratories, Hercules, CA, USA).

Qualitative HIV-1 DNA PCR was performed on all available birth, 2-month and 6-month infant venous blood samples. An aliquot of these samples, collected in EDTA anticoagulant, was prepared in Bangkok as a leukocyte DNA lysate and frozen in liquid nitrogen. Diagnostic PCR was performed in duplicate on batched, coded samples and negative and positive controls using two sets of gag primer pairs, SK38/39 and SK145/150. This CDC PCR assay is estimated to detect a minimum of 10 proviral copies/25μl of DNA lysate, representing approximately 150000 leukocytes.

Quantitative HIV-1 RNA PCR was performed on coded maternal delivery plasma samples using the Amplicor HIV-1 Monitor Test Kit, version 1.0 (Roche Diagnostic Systems, Inc., Branchburg, NJ, USA) according to the manufacturer‚s instructions with some modifications. A new primer mix (SK145 and SK151), provided by Roche, was added (10μl) to efficiently quantify RNA of HIV-1 subtype E. This modification gives similar results to those obtained with the new primer set included in version 1.5. The starting specimen volume was 200μl. With this volume the assay has a threshold sensitivity of 200 HIV RNA copies/ml and a linear range for quantification of 400-750000 copies/ml.

Lymphocyte phenotyping was performed on fresh mother and infant venous blood samples collected in EDTA collection tubes using the FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) and a standard six-tube, two-color monoclonal antibody panel (Becton Dickinson). NK cells were defined as CD3-, CD16+ and CD56+.

Back to Top | Article Outline
Definition of infant HIV-1 infection

Infants were considered to be HIV-1-infected if they had two HIV-1-positive DNA PCR tests, or one positive PCR test and a CDC AIDS-defining condition. Infants were defined as uninfected if they tested PCR HIV-1-negative on two samples, including one obtained at 6 months of age or older, or if they seroreverted to HIV-negative status on EIA testing. Infants not meeting these criteria were considered to have unknown infection status.

Back to Top | Article Outline
Study sample and definition of time of transmission

Mother-infant pairs with known transmission outcomes were included in this analysis if the infant had a PCR test result on a sample obtained within 72 h of birth (birth sample). The time of birth and time of specimen collection were both recorded, and the time (h) after birth was calculated. Among infected infants, in utero infection was presumed if the birth PCR test result was positive. Otherwise, infection was presumed to have occurred intrapartum.

Back to Top | Article Outline
Statistical analysis

To investigate factors associated with timing of perinatal HIV transmission two comparisons were made: (i) in utero-infected infants (positive birth PCR) versus all infants with a negative birth PCR test result (uninfected infants and intrapartum-infected infants); and (ii) intrapartum-infected infants versus uninfected infants. Exact binomial 95% confidence intervals (CI) were calculated for the estimated HIV transmission rates. Continuous variables, including maternal RNA level, CD4+ T-lymphocyte and NK cell absolute values and percentages, duration of ruptured membranes and duration of labor were dichotomized at the overall sample median or at values reported by others. One woman had a viral level below detection; she was assigned a value of 100 copies/ml for statistical analysis. Frequency data were analyzed by χ2 (or Fisher‚s exact) or χ2 for trend tests. Odds ratios (OR) and mid-P 95% CI were computed as the measure of effect [17]. Multivariate analyses were performed using multiple logistic regression, adjusted OR were estimated and 95% CI were computed.

To test whether a risk factor was related to time of transmission, a nested response logistic regression model was used [18]. The model as applied here is a discrete time survival model [19]; the grouped time points of infection were in utero and intrapartum. Constancy of effect, or homogeneity of OR, was assessed by testing the significance of an interaction term between the risk factor and time of transmission in the logistic model. The population-attributable fraction was estimated for maternal viral load at different reference cut-off points by logistic regression, adjusted for other significant risk factors [20]. CI were calculated on the logit scale [21].

Back to Top | Article Outline

Results

Of 295 HIV-infected pregnant women who delivered during the study, 281 (95.3%) had infants with known HIV-infection status. There was a total of 68 infected infants and the overall transmission rate was 24.2%. Sixty-one of the infected infants (90%) had two or more positive PCR tests; the other seven infected infants met the alternate definition for infection.

Of the 281 mother-infant pairs with known transmission outcome, 218 (78%), including 49 (72%) of the 68 infected infants, had a PCR test result for a specimen collected within 72 h of birth, and were included in this analysis. There were no significant differences (data not shown) in mother‚s age or any maternal, delivery, or other perinatal factors between the 218 infants with a birth PCR result and the 63 additional infants with known infection outcomes but without a birth PCR result. There were also no significant differences in factors among infected children included in or excluded from the birth PCR analysis. The median time of collection of the birth sample was 22 h; 82% of samples were collected within 48 h of birth.

For the 218 infants with a birth PCR test result, the overall HIV transmission rate was 22.5% (Table 1). Twelve infected infants tested HIV-1 positive by PCR at birth, giving an in utero transmission rate of 5.5%. Thirty-seven infected infants tested HIV-1 negative at birth and subsequently tested HIV-1 positive, giving an intrapartum transmission rate of 18.0%. PCR testing at birth detected 12 out of 49 infected infants, suggesting that 24.5% (95% CI, 14.0-37.9) of transmissions occurred in utero and 75.5% occurred intrapartum. Similar results were obtained when the analysis was limited to samples collected within 48 h of birth.

Table 1
Table 1
Image Tools

High maternal viral load at delivery and low birth-weight (<2500g) were independently associated with in utero transmission (Table 2). Maternal viral load above the sample median (18500 copies/ml), which included 10 (83%) out of 12 in utero infections, was associated with a 5.8-fold (95% CI, 1.4-38.8) increased adjusted odds of transmission. When analyzed as a continuous variable, the adjusted odds of transmission was 2.9 (95% CI, 1.2-7.8) per unit log increase in maternal viral load. Low birth-weight also was associated with in utero transmission [adjusted OR (AOR), 5.6; 95% CI, 1.3-21.1]: one-third of infants infected in utero were low birth-weight. Pre-term infants (<37 weeks gestational age, by modified Ballard) had a 25% risk for in utero transmission compared to 5% for full-term infants (OR, 6.7; 95% CI, 0.8-35.6), although this was not statistically significant. Maternal immunological markers, such as CD4+ T-lymphocyte and NK cell percentage and absolute count (not shown), and obstetric factors such as mode of delivery and duration of membrane rupture and labor, were not associated with in utero transmission. However, because the number of cases was small, this analysis had limited power to identify factors associated with in utero transmission.

Table 2
Table 2
Image Tools

Maternal delivery viral load was also strongly associated with intrapartum transmission (Table 3), whether dichotomized at the sample median (AOR, 4.4) or analyzed as a continuous variable (AOR, 2.31/log increase). In addition, low CD4+ T-lymphocyte and low NK cell percentages were associated with increased intrapartum transmission (the absolute counts for these variables were not associated with transmission). Delivery by cesarean section appeared to be protective for intrapartum transmission (11.1% transmission versus 19.0% for vaginal delivery), but the number of cesarean births with a PCR result was small (n = 27) and this association was not significant. There was no suggestion that other obstetric factors, or prematurity and low birth-weight, were associated with intrapartum transmission. Lack of association for duration of ruptured membranes and length of labor was still observed when cesarean deliveries were excluded from the analysis.

Table 3
Table 3
Image Tools

To evaluate whether factors found to be associated with in utero or intrapartum transmission were dependent on time of transmission, a nested logistic model was fitted to the data and was tested for interaction between the factor and time of transmission (not shown). Maternal viral load was not associated with time of transmission (P=0.99 for no interaction), as elevated viral load was associated significantly with increased risk for both in utero and intrapartum transmission. In addition, viral load among mothers who transmitted in utero (mean, 4.7 log10) was comparable to viral load among mothers who transmitted intrapartum (mean, 4.6 log10; P=0.6). The effects of NK cell percentage were not related to time of transmission (P=0.9); they were in the same direction and magnitude for both in utero and intrapartum transmission, but associated significantly with intrapartum transmission only (Table 3). The non-significant association with in utero transmission was probably due to low power. In contrast, the effects of low birth-weight (P=0.03) and maternal CD4+ T-lymphocyte percentage (P=0.02) were associated with time of transmission. Low birth-weight was significantly associated with in utero transmission (Table 2), whereas its effect for intrapartum transmission showed a trend in the opposite direction (Table 3). Conversely, CD4+ T-lymphocyte percentage was associated significantly with intrapartum transmission; its effect for in utero transmission also showed a trend in the opposite direction. For the two risk factors related to time of transmission, infants infected in utero were compared directly with infants infected intrapartum. Infants infected in utero were more likely to be of low birth-weight (OR, 8.8; 95% CI, 1.3-74.8) and infants infected intrapartum were more likely to have mothers with a CD4+ T-lymphocyte percentage <21% (OR, 4.9; 95% CI, 1.1-25.5).

Because maternal viral load was associated with both in utero and intrapartum transmission and is amenable to direct intervention, the population-attributable fractions for different viral load cut-off points were estimated (Table 4). Adjusted for low birth-weight, the population-attributable fraction for in utero transmission was 67% for maternal viral levels greater than the sample median of 18500 copies/ml (4.27 log10). Because of the small number of in utero infections, more extensive analysis of different cut-off points was not possible. For intrapartum transmission, adjusted for NK and CD4+ T-lymphocyte percentages, the population-attributable fraction was 53% for maternal viral levels greater than the median, and 69% for levels greater than 10000 copies/ml (4log10). Table 4 also shows the level-specific estimates for half-log increments in viral load from 4log10 to greater than 5log10.

Table 4
Table 4
Image Tools
Back to Top | Article Outline

Discussion

Using the current working definition of timing of perinatal transmission in a cohort of non-breastfed infants born to HIV-1 subtype E-infected mothers in Bangkok, this study confirms that approximately three-quarters of HIV-infected infants are infected intrapartum and has found that maternal plasma viral load at delivery is a strong, independent risk factor for both in utero and intrapartum transmission. This is important because maternal viral load should be amenable to direct intervention.

To our knowledge, this is the first analysis that has evaluated the relationship between maternal viral load and timing of perinatal HIV transmission. Clear evidence was found that elevated maternal viral load is a strong risk factor for both in utero and intrapartum transmission. Whereas in utero transmission is probably associated with cell-free or cell-associated virus crossing the placenta, increased intrapartum risk may be due to maternal-infant transfusions, disruptions of the placental barrier or direct contact with maternal blood or mucosal secretions in the vaginal canal. The finding that viral load, as a determinant of transmission, is independent of timing was anticipated in a recent review [4], but this study provides the first evidence to support this hypothesis. This finding suggests that intervention strategies aimed at reducing maternal viral load might be successful at reducing both in utero and intrapartum transmission.

The population-attributable fraction is an estimate of the reduction in transmission that might be expected if a risk factor could be eliminated. For in utero transmission, the population-attributable fraction associated with viral load greater than the sample median was 67%. Because of the small number of cases, it was not possible to explore further the relationship between viral load and in utero transmission. Further investigations and combined analysis may help to define this relationship better. For intrapartum transmission, the population-attributable fraction estimate was 53% for viral load greater than the median and 69% for levels greater than 10000 copies/ml. Below 10000 copies/ml, intrapartum transmission risk appeared to be low (<5%). In this population sample, viral load reductions to below 10000 copies/ml at delivery would be achieved for most women with an intervention that produces a 0.5-1 log10 reduction. Our data did not suggest that the magnitude of effect obtained by reducing viral load may be more important for in utero transmission, but this should be examined in other studies. Short-course antiretroviral intervention studies targeted at preventing late in utero and intrapartum perinatal HIV transmission currently in progress in developing countries, including a study recently concluded by our group which showed a 50% reduction in transmission [22,23], may help to confirm the role of maternal viral load and timing of transmission.

Our estimate that 25% of infected infants are infected in utero is the same as estimates reported in CDC studies in Zaire and New York [6,7] and is consistent with estimates of approximately 35% reported in other studies [8,9,11]. Differences may be due to different PCR methods, the completeness of the sample, and the time of the ‚birth sample‚ collection. Using birth DNA PCR results (within 2-3 days of birth), it is difficult to distinguish late in utero transmission from intrapartum transmission because the window before detecting HIV DNA in the blood may vary and may be as long as 1 week [6,9,11]. Additional analyses with more sensitive, standardized assays such as RNA PCR, may help to distinguish better between in utero and intrapartum transmission. Nevertheless, the consistent conclusion from studies worldwide, conducted in populations with different HIV-1 subtypes, is that in the absence of breastfeeding most perinatal HIV infections (65-75%) occur during labor and delivery. This suggests that most perinatal transmission, in the absence of breastfeeding, may be amenable to short-term interventions targeted at the end of pregnancy.

In this analysis, the overall mother-to-child HIV transmission rate was 22.5% (95% CI, 17.3-28.4), a result consistent with other transmission estimates in women who did not breastfeed and who did not receive antiretroviral therapy [2,3]. An absolute in utero transmission rate of 5.5% (95% CI, 3.0-9.2) was estimated; this is again consistent with previous estimates from New York [7] and Africa [6,10]. In addition, the absolute intrapartum transmission rate was estimated to be 18% (95% CI, 13.2-23.7), almost identical to rates reported in Africa, with breastfeeding [6,10], but somewhat higher than the 13% rate reported in New York [7]. Intrapartum transmission may be more variable than in utero transmission.

We recently reported that low maternal NK cell percentage was a risk factor for HIV-1 transmission [15]. In the current analysis, it was found that the NK cell association was independent of time of transmission. NK cells are a marker for cell-mediated immunity, and NK cell number declines in HIV-infected individuals [24]. Decreased maternal cell-mediated immunity has been associated with perinatal transmission and has been hypothesized to be a risk factor for in utero transmission [4]. The present NK cell results suggest that maternal cell-mediated immunity can influence transmission directly, independently of viral load [1], particularly at delivery. Functional studies might help to clarify the relationship between NK cell number and activity. If these NK cell findings are confirmed in other studies, then NK cell percentage might be used as a marker to target women at high risk for transmission. Our finding that lower CD4+ T-lymphocyte percentage at delivery was associated with increased risk of intrapartum transmission further supports the hypothesis that maternal immunosuppression at delivery is a risk factor for intrapartum transmission, but the mechanism and the opportunities for intervention are not clear.

Low birth-weight and prematurity have been associated with perinatal HIV transmission in numerous studies, including ours. Although these factors are hypothesized to be associated with in utero infection, there have been no data to support this, and debate continues over whether low birth-weight and prematurity result from or predispose to infection [1,25]. In one African study, there was no relationship between birth-weight and timing [9]. In New York, low birth-weight and prematurity were associated with intrapartum transmission [7]. In the current analysis, low birth-weight was associated with in utero transmission, as was prematurity, although the association with prematurity was borderline. Contrary to the New York study, low birth-weight and prematurity were not associated with intrapartum transmission. Some of the difference may be due to differences in the causes of low birth-weight and prematurity in the two populations and to differences in the occurrence of these conditions. For example, in the Bangkok study, there was virtually no smoking or drug use, antenatal registration was early and regular, and women received multivitamin supplements. Interestingly, in these two cohorts of HIV-infected women, the prevalence of low birth-weight infants in Bangkok was 10%, whereas in New York it was 28% [7]. Exclusion of low birth-weight from the present analyses, because of concern about whether it is a cause or consequence of HIV infection, does not change the other conclusions.

It was expected that obstetric factors would be found to be associated with intrapartum transmission [1,4]. However, neither mode of delivery, duration of ruptured membranes nor length of labor were independent risk factors for intrapartum transmission. Longer duration of ruptured membranes among vaginal deliveries was associated with intrapartum transmission in the New York study [7]. One explanation for the difference in findings might be that women in the present study had shorter duration of ruptured membranes and few had prolonged ruptured membranes. In the complete cohort, cesarean section was protective for overall mother-to-child transmission [15]. However in the reduced sample, the protective effect of cesarean section for intrapartum transmission was not significant.

In summary, this study demonstrates that maternal viral load, as measured at delivery, is strongly associated with both in utero and intrapartum HIV-1 perinatal transmission, and suggests that interventions aimed at reducing maternal viral load may be effective in reducing transmission at both of these times. The results reported here provide further evidence that as much as 75% of perinatal HIV-1 infections occur during labor and delivery, and suggest that a successful intervention offered late in pregnancy could reduce substantially both intrapartum and overall transmission risk. These findings may help to explain the success, in the absence of breastfeeding, of short-course zidovudine given in late pregnancy and delivery to reduce perinatal transmission [22].

Back to Top | Article Outline

Acknowledgments

The authors thank R.J. Simonds and J. Karon for critical review of the manuscript, V. Batter and L. Carr for assistance with data management and analysis, J. Rapier for DNA PCR testing, T. Granade and S. Philips for RNA PCR testing, and W. Pokapanichwong, J. Laosakkitiboran and P. Yuentrakul, for coordinating the field study. We gratefully acknowledge the dedicated field work of the study nurses and social workers: K. Neeyapun, P. Tothong and S. Pinyovanichkul (team leaders); N. Chookaew, S. Henchaichon, S. Jalanchavanapate, B. Jetsawang, K. Klumthanom, S. Phurksakusamesuk, C. Prasert, S. Samsukkree, S. Sorapipatana, S. Suwanmaitre and C. Yuvasevee.

Back to Top | Article Outline

References

1. John GC, Kreiss J: Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev 1996, 18:149-157.

2. The Working Group on Mother-to-Child Transmission of HIV: Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: Results from 13 Perinatal Studies. J Acquir Immun Defic Syndr Hum Retrovirol 1995, 8:506-510.

3. Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996, 335:1621-1629.

4. Bryson YJ: Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS 1996, 10 (suppl 3): S33-S42.

5. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW: Proposed definition for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992, 327:1246-1247.

6. Bertolli J, St Louis ME, Simonds RJ, et al.: Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J Infect Dis 1996, 174:722-726.

7. Kuhn L, Abrams EJ, Matheson PB, et al.: Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS 1997, 11:429-435.

8. Rouzioux C, Costagliola D, Burgard M, et al.: Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995, 142:1330-1337.

9. Biggar RJ, Mtimavalye L, Justesen A, et al.: Does umbilical cord blood polymerase chain reaction positivity indicate in utero (pre-labor) HIV infection? AIDS 1997, 11:1375-1382.

10. Simonon A, Lepage P, Karita E, et al.: An assessment of the timing of mother-to-child transmission of human immunodeficiency virus type 1 by means of polymerase chain reaction. J Acquir Immun Defic Syndr Hum Retrovirol 1994, 7:952-957.

11. Dunn DT, Brandt CD, Krivine A, et al.: The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995, 9:F7-F11.

12. Rich KC, Chang B, Mofenson L, et al.: Elevated CD8+DR+ lymphocytes in HIV-exposed infants with early positive HIV cultures: a possible early marker of intrauterine transmission. J Acquir Immun Defic Syndr Hum Retrovirol 1997, 15:204-210.

13. Chouquet C, Burgard M, Richardson S, Rouzioux C, Costagliola D: Timing of mother-to-child HIV-1 transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric method [letter]. AIDS 1997, 11:1183-1184.

14. Shaffer N, Bhiraleus P, Chinayon P, et al.: High viral load predicts perinatal HIV-1 subtype E transmission, Bangkok, Thailand. XI International Conference on AIDS. Vancouver, July 1996 [abstract 247].

15. Shaffer N, Roongpisuthipong A, Siriwasin W, et al.: Maternal viral load and perinatal HIV-1 subtype E transmission, Bangkok, Thailand. J Infect Dis 1999, in press.

16. Siriwasin W, Shaffer N, Roongpisuthipong A, et al.: HIV prevalence, risk factors and partner serodiscordance among pregnant women, Bangkok, Thailand. JAMA 1998, 280:49-54.

17. Armitage P, Berry G: Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publications; 1994.

18. McCullagh P, Nelder JA: Generalized Linear Models. London: Chapman and Hall; 1989.

19. Abbott RD: Logistic regression in survival analysis. Am J Epidemiol 1985, 121:465-471.

20. Greenland S, Drescher K: Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 1993, 49:865-872.

21. Greenland S: Variance estimators for attributable fraction estimates consistent in both large strata and sparse data. Stat Med 1987; 6:701-708.

22. Centers for Disease Control and Prevention: Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998. MMWR 1998, 47:151-153.

23. Shaffer N, Chuachoowong R, Mock PA, et al.: Randomised placebo-controlled trial of short-course antenatal zidovudine to reduce perinatal HIV transmission, Bangkok, Thailand. Lancet 1999, in press.

24. Lucia B, Jennings C, Cauda R, Ortona L, Landay AL: Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer subset during HIV infection. Cytometry 1995, 22:10-15.

25. European Collaborative Study: Risk factors for mother-to-child transmission of HIV-1. Lancet 1992, 339:1007-1012.

Cited By:

This article has been cited 79 time(s).

Journal of the International AIDS Society
Frequency and factors associated with adherence to and completion of combination antiretroviral therapy for prevention of mother to child transmission in western Kenya
Ayuo, P; Musick, B; Liu, H; Braitstein, P; Nyandiko, W; Otieno-Nyunya, B; Gardner, A; Wools-Kaloustian, K
Journal of the International AIDS Society, 16(): -.
ARTN 17994
CrossRef
Current Hiv Research
The Role of Co-Infections in Mother-to-Child Transmission of HIV
King, CC; Ellington, SR; Kourtis, AP
Current Hiv Research, 11(1): 10-23.

Memorias DO Instituto Oswaldo Cruz
Vertical human immunodeficiency virus type 1 - HIV-1 - Transmission - A review
Bongertz, V
Memorias DO Instituto Oswaldo Cruz, 96(1): 1-14.

Modern Pathology
Chorioamnionitis is associated with placental transmission of human immunodeficiency virus-1 subtype E in the early gestational period
Bhoopat, L; Khunamornpong, S; Sirivatanapa, P; Rithaporn, T; Lerdsrimongkol, P; Thorner, PS; Bhoopat, T
Modern Pathology, 18(): 1357-1364.
10.1038/modpathol.3800418
CrossRef
American Journal of Epidemiology
Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand
Hudgens, MG; Longini, IM; Vanichseni, S; Hu, DJ; Kitayaporn, D; Mock, PA; Halloran, ME; Satten, GA; Choopanya, K; Mastro, TD
American Journal of Epidemiology, 155(2): 159-168.

Lancet
Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial
Saba, J; Haverkamp, G; Gray, G; McIntyre, J; Mmiro, F; Ndugwa, C; Coovadia, HM; Moodley, J; Kilewo, C; Massawe, A; Kituuka, P; Okong, P; von Briesen, H; Goudsmit, J; Biberfeld, G; Grulich, A; Weverling, GJ; Lange, JMA
Lancet, 359(): 1178-1186.

Current Hiv Research
Mother-to-child transmission of HIV infection and its prevention
Thorne, C; Newell, ML
Current Hiv Research, 1(4): 447-462.

Samj South African Medical Journal
Identifying acute HIV infection - a major new public health challenge
Motloung, T; Myers, M; Venter, F; Delany, S; Rees, H; Stevens, W
Samj South African Medical Journal, 94(7): 531.

Virology
Differential expression and interaction of host factors augment HIV-1 gene expression in neonatal mononuclear cells
Sundaravaradan, V; Mehta, R; Harris, DT; Zack, JA; Ahmad, N
Virology, 400(1): 32-43.
10.1016/j.virol.2010.01.018
CrossRef
New England Journal of Medicine
Reducing the risk of maternal-infant transmission of HIV by attacking the virus
Rogers, MF; Shaffer, N
New England Journal of Medicine, 341(6): 441-443.

Jama-Journal of the American Medical Association
Prevention of mother-to-child HIV transmission in resource-poor countries - Translating research into policy and practice
De Cock, KM; Fowler, MG; Mercier, E; de Vincenzi, I; Saba, J; Hoff, E; Alnwick, DJ; Rogers, M; Shaffer, N
Jama-Journal of the American Medical Association, 283(9): 1175-1182.

AIDS
Thai Red Cross zidovudine donation program to prevent vertical transmission of HIV: the effect of the modified ACTG 076 regimen
Thisyakorn, U; Khongphatthanayothin, M; Sirivichayakul, S; Rongkavilit, C; Poolcharoen, W; Kunanusont, C; Bien, DD; Phanuphak, P
AIDS, 14(): 2921-2927.

New England Journal of Medicine
Viral load and heterosexual transmission of human immunodeficiency virus type 1
Quinn, TC; Wawer, MJ; Sewankambo, N; Serwadda, D; Li, CJ; Wabwire-Mangen, F; Meehan, MO; Lutalo, T; Gray, RH
New England Journal of Medicine, 342(): 921-929.

Pediatrics
Gender differences in perinatal HIV acquisition among African infants
Taha, TE; Nour, S; Kumwenda, NI; Broadhead, RL; Fiscus, SA; Kafulafula, G; Nkhoma, C; Chen, S; Hoover, DR
Pediatrics, 115(2): E167-E172.
10.1542/peds.2004-1590
CrossRef
Prevention and Treatment of Hiv Infection in Infants and Children
Genital tract infections and perinatal transmission of HIV
Taha, TE; Gray, RH
Prevention and Treatment of Hiv Infection in Infants and Children, 918(): 84-98.

New England Journal of Medicine
Drug therapy - Management of human immunodeficiency virus infection in pregnancy
Watts, DH
New England Journal of Medicine, 346(): 1879-1891.

Food and Drug Law Journal
Ethics of AIDS clinical trials in developing countries: A review
Pitler, LR
Food and Drug Law Journal, 57(1): 133-153.

AIDS Research and Human Retroviruses
Role of placental cytokines in transcriptional modulation of HIV type 1 in the isolated villous trophoblast
Zachar, V; Fink, T; Koppelhus, U; Ebbesen, P
AIDS Research and Human Retroviruses, 18(): 839-847.

Journal of Infectious Diseases
Comparative prediction of perinatal human immunodeficiency virus type 1 transmission, using multiple virus load markers
Montano, M; Russell, M; Gilbert, P; Thior, I; Lockman, S; Shapiro, R; Chang, SY; Lee, TH; Essex, M
Journal of Infectious Diseases, 188(3): 406-413.

British Journal of Clinical Pharmacology
Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women
Roustit, M; Jlaiel, M; Leclercq, P; Stanke-Labesque, F
British Journal of Clinical Pharmacology, 66(2): 179-195.
10.1111/j.1365-2125.2008.03220.x
CrossRef
Lancet
Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load - Reply
Shaffer, N; Siriwasin, W; Bhadrakom, C; Chotplayasunondh, T; Chearskul, S
Lancet, 354(): 157-158.

Drug and Alcohol Dependence
HIV-1 RNA load in needles/syringes from shooting galleries in Miami: a preliminary laboratory report
Shapshak, P; Fujimura, RK; Page, JB; Segal, D; Rivers, JE; Yang, J; Shah, SM; Graham, G; Metsch, L; Weatherby, N; Chitwood, DD; McCoy, CB
Drug and Alcohol Dependence, 58(): 153-157.

Early Human Development
Epidemiology of HIV infection in the newborn
Thorne, C; Newell, ML
Early Human Development, 58(1): 1-16.

Journal of Acquired Immune Deficiency Syndromes
Prenatal transmission of subtype CHIV-1 in Zimbabwe: HIV-1 RNA and DNA in maternal and cord blood
Guevara, H; Johnston, E; Zijenah, L; Tobaiwa, O; Mason, P; Contag, C; Mahomed, K; Hendry, M; Katzenstein, D
Journal of Acquired Immune Deficiency Syndromes, 25(5): 390-397.

Journal of Acquired Immune Deficiency Syndromes
Epidemiologic and clinical features of HIV-infected and HIV-uninfected Ugandan children younger than 18 months
Bakaki, P; Kayita, J; Machado, JEM; Coulter, JBS; Tindyebwa, D; Ndugwa, CM; Hart, CA
Journal of Acquired Immune Deficiency Syndromes, 28(1): 35-42.

Journal of Infectious Diseases
Lack of association between human immunodeficiency virus type 1 antibody in cervicovaginal lavage fluid and plasma and perinatal transmission, in Thailand
Chuachoowong, R; Shaffer, N; VanCott, TC; Chaisilwattana, P; Siriwasin, W; Waranawat, N; Vanprapar, N; Young, NL; Mastro, TD; Lambert, JS; Robb, ML
Journal of Infectious Diseases, 181(6): 1957-1963.

Drug Resistance Updates
Mother-to-child transmission of drug-resistant HIV
Kijak, GH; Avila, MM; Salomon, H
Drug Resistance Updates, 4(1): 29-37.
10.1054/drup.2001.0182
CrossRef
Antiviral Therapy
Cervicovaginal HIV-1 shedding in pregnant women near delivery
Saracino, A; Di Stefano, M; Vimercati, A; Greco, P; Fiore, JR; Monno, L; Angarano, G; Pastore, G
Antiviral Therapy, 6(1): 79-81.

Journal of Obstetrics and Gynaecology Research
Risk factors of preterm delivery in HIV-infected pregnant women receiving zidovudine for the prevention of perinatal HIV
Traisathit, P; Mary, JY; Le Coeur, S; Thantanarat, S; Jungpichanvanich, S; Pornkitprasarn, W; Gomutbutra, V; Matanasarawut, W; Wannapira, W; Lallemant, M
Journal of Obstetrics and Gynaecology Research, 35(2): 225-233.
10.1111/j.1447-0756.2008.00925.x
CrossRef
Diagnostic Microbiology and Infectious Disease
Acute HIV infection among pregnant women in Malawi
Gay, CL; Mwapasa, V; Murdoch, DM; Kwiek, JJ; Fiscus, SA; Meshnick, SR; Cohen, MS
Diagnostic Microbiology and Infectious Disease, 66(4): 356-360.
10.1016/j.diagmicrobio.2009.12.001
CrossRef
Pediatric Clinics of North America
Update on perinatal HIV transmission
Fowler, MG; Simonds, RJ; Roongpisuthipong, A
Pediatric Clinics of North America, 47(1): 21-+.

AIDS
Interventions to prevent vertical transmission of HIV-1: effect on viral detection rate in early infant samples
Dunn, DT; Simonds, RJ; Bulterys, M; Kalish, LA; Moye, J; de Maria, A; Kind, C; Rudin, C; Denamur, E; Krivine, A; Loveday, C; Newell, ML
AIDS, 14(): 1421-1428.

Journal of Acquired Immune Deficiency Syndromes
Early diagnosis of HIV-1-infected infants in Thailand using RNA and DNA PCR assays sensitive to non-B subtypes
Young, NL; Shaffer, N; Chaowanachan, T; Chotpitayasunondh, T; Vanparapar, N; Mock, PA; Waranawat, N; Chokephaibulkit, K; Chuachoowong, R; Wasinrapee, P; Mastro, TD; Simonds, RJ
Journal of Acquired Immune Deficiency Syndromes, 24(5): 401-407.

Journal of Infectious Diseases
Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/mL
Ioannidis, JPA; Abrams, EJ; Ammann, A; Bulterys, M; Goedert, JJ; Gray, L; Korber, BT; Mayaux, MJ; Mofenson, LM; Newell, ML; Shapiro, DE; Teglas, JP; Wilfert, CM
Journal of Infectious Diseases, 183(4): 539-545.

Journal of Acquired Immune Deficiency Syndromes
HIV seroconversion during pregnancy and risk for mother-to-infant transmission
Roongpisuthipong, A; Siriwasin, W; Simonds, RJ; Sangtaweesin, V; Vanprapar, N; Wasi, C; Singhanati, S; Mock, P; Young, N; Parekh, B; Mastro, TD; Shaffer, N
Journal of Acquired Immune Deficiency Syndromes, 26(4): 348-351.

Journal of Infectious Diseases
Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe
Katzenstein, DA; Mbizvo, M; Zijenah, L; Gittens, T; Munjoma, M; Hill, D; Madzime, S; Maldonado, Y
Journal of Infectious Diseases, 179(6): 1382-1387.

Journal of Acquired Immune Deficiency Syndromes
The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States
Zaric, GS; Bayoumi, AM; Brandeau, ML; Owens, DK
Journal of Acquired Immune Deficiency Syndromes, 25(5): 403-416.

Pediatrics
Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort
Peters, V; Liu, KL; Dominguez, K; Frederick, T; Melville, S; Hsu, HW; Ortiz, I; Rakusan, T; Gill, B; Thomas, P
Pediatrics, 111(5): 1186-1191.

Yonsei Medical Journal
Anesthetic considerations for the HIV-infected pregnant patient
Kuczkowski, KM
Yonsei Medical Journal, 45(1): 1-6.

Bjog-An International Journal of Obstetrics and Gynaecology
Exploring the mechanisms of intrapartum transmission of HIV. Does elective caesarean section hold the key?
de Vries, BS; Peek, MJ
Bjog-An International Journal of Obstetrics and Gynaecology, 115(6): 677-680.
10.1111/j.1471-0528.2008.01693.x
CrossRef
Scandinavian Journal of Immunology
Vertical HIV-1 transmission: Importance of neutralizing antibody titer and specificity
Bongertz, V; Costa, CI; Veloso, VG; Grinsztejn, B; Joao, EC; Calvet, G; Pilotto, JH; Guimaraes, ML; Morgado, MG
Scandinavian Journal of Immunology, 53(3): 302-309.

AIDS Reviews
Mother-to-child transmission of HIV-1: Advances and controversies of the twentieth centuries
Scarlatti, G
AIDS Reviews, 6(2): 67-78.

Journal of Medical Virology
Mother to Child Transmission of HIV-1 in a Thai Population: Role of Virus Characteristics and Maternal Humoral Immune response
Kittinunvorakoon, C; Morris, MK; Neeyapun, K; Jetsawang, B; Buehring, GC; Hanson, CV
Journal of Medical Virology, 81(5): 768-778.
10.1002/jmv.21465
CrossRef
Journal of Acquired Immune Deficiency Syndromes
Maternal HIV-1 antibody and vertical transmission in subtype C virus infection
Guevara, H; Casseb, J; Zijenah, LS; Mbizvo, M; Oceguera, LF; Hanson, CV; Katzenstein, DA; Hendry, RM
Journal of Acquired Immune Deficiency Syndromes, 29(5): 435-440.

Journal of Obstetrics and Gynaecology Research
Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries
Hashimoto, H; Kapiga, SH; Murata, Y
Journal of Obstetrics and Gynaecology Research, 28(6): 313-319.

Journal of Infectious Diseases
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1
Moodley, D; Moodley, J; Coovadia, H; Gray, G; McIntyre, J; Hofmyer, J; Nikodem, C; Hall, D; Gigliotti, M; Robinson, P; Boshoff, L; Sullivan, JL
Journal of Infectious Diseases, 187(5): 725-735.

Journal of Virology
Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates
McDermott, AB; Mitchen, J; Piaskowski, S; De Souza, I; Yant, LJ; Stephany, J; Furlott, J; Watkins, DI
Journal of Virology, 78(6): 3140-3144.
10.1128/JVI.78.6.3140-3144.2004
CrossRef
Cochrane Database of Systematic Reviews
Vaginal disinfection for preventing mother-to-child transmission of HIV infection
Wiysonge, CS; Shey, MS; Shang, JD; Sterne, JAC; Brocklehurst, P
Cochrane Database of Systematic Reviews, (4): -.
ARTN CD003651
CrossRef
Journal of Antimicrobial Chemotherapy
Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment
Bouillon-Pichault, M; Jullien, V; Azria, E; Pannier, E; Firtion, G; Krivine, A; Compagnucci, A; Taulera, O; Finkielsztejn, L; Chhun, S; Pons, G; Launay, O; Treluyer, JM
Journal of Antimicrobial Chemotherapy, 63(6): 1223-1232.
10.1093/jac/dkp123
CrossRef
Journal of Infectious Diseases
Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission
Chuachoowong, R; Shaffer, N; Siriwasin, W; Chaisilwattana, P; Young, NL; Mock, PA; Chearskul, S; Waranawat, N; Chaowanachan, T; Karon, J; Simonds, RJ; Mastro, TD
Journal of Infectious Diseases, 181(1): 99-106.

South African Journal of Science
Antiretroviral treatment to prevent mother-to-child transmission of HIV-1
McIntyre, J; Gray, G
South African Journal of Science, 96(6): 277-280.

Journal of Infectious Diseases
Placental abnormalities associated with human immunodeficiency virus type 1 infection and perinatal transmission in Bangkok, Thailand
Schwartz, DA; Sungkarat, S; Shaffer, N; Laosakkitiboran, J; Supapol, W; Charoenpanich, P; Chuangsuwanich, T; Mastro, TD
Journal of Infectious Diseases, 182(6): 1652-1657.

Antimicrobial Agents and Chemotherapy
Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1
Kashuba, ADM; Dyer, JR; Kramer, LM; Raasch, RH; Eron, JJ; Cohen, MS
Antimicrobial Agents and Chemotherapy, 43(8): 1817-1826.

Journal of Clinical Anesthesia
Human immunodeficiency virus in the parturient
Kuczkowski, KM
Journal of Clinical Anesthesia, 15(3): 224-233.
10.1016/S0952-8180(03)00029-1
CrossRef
American Journal of Health-System Pharmacy
Update on preventing vertical transmission of HIV type 1
Chen, F; Pau, AK; Piscitelli, SC
American Journal of Health-System Pharmacy, 57(): 1616-1623.

Journal of Acquired Immune Deficiency Syndromes
Placental inflammation and perinatal transmission of HIV-1
Mwanyumba, F; Gaillard, P; Inion, I; Verhofstede, C; Claeys, P; Chohan, V; Vansteelandt, S; Mandaliya, K; Praet, M; Temmerman, M
Journal of Acquired Immune Deficiency Syndromes, 29(3): 262-269.

European Journal of Obstetrics Gynecology and Reproductive Biology
HIV detection in amniotic fluid samples - Amniocentesis can be performed in HIV pregnant women?
Maiques, V; Garcia-Tejedor, A; Perales, A; Cordoba, J; Esteban, RJ
European Journal of Obstetrics Gynecology and Reproductive Biology, 108(2): 137-141.
PII S0301-2115(02)00405-0
CrossRef
International Journal of Gynecology & Obstetrics
Duration of ruptured membranes and extended labor are risk factors for HIV transmission
Garcia-Tejedor, A; Perales, A; Maiques, V
International Journal of Gynecology & Obstetrics, 82(1): 17-23.
10.1016/S0020-7292(03)00123-1
CrossRef
American Journal of Public Health
Trends in perinatal HIV prevention in New York City, 1994-2003
Peters, VB; Liu, KL; Robinson, LG; Dominguez, KL; Abrams, EJ; Gill, BS; Thomas, PA
American Journal of Public Health, 98(): 1857-1864.
10.2105/AJPH.2007.110023
CrossRef
Vaccine
Use of predictive markers of HIV disease progression in vaccine trials
Gurunathan, S; El Habib, R; Baglyos, L; Meric, C; Plotkin, S; Dodet, B; Corey, L; Tartaglia, J
Vaccine, 27(): 1997-2015.
10.1016/j.vaccine.2009.01.039
CrossRef
Enfermedades Infecciosas Y Microbiologia Clinica
Prevention of vertical transmission and treatment of infection caused by the human immunodeficiency virus in the pregnant woman
Iribarren, JA; Ramos, JT; Guerra, L; Coll, O; de Jose, MI; Domingo, P; Fortuny, C; Miralles, P; Parras, F; Pena, JM; Rodrigo, C; Vidal, R
Enfermedades Infecciosas Y Microbiologia Clinica, 19(7): 314-335.

Journal of Clinical Anesthesia
Anesthetic management of the parturient with fever and infection
Kuczkowski, KM; Reisner, LS
Journal of Clinical Anesthesia, 15(6): 478-488.
10.1016/S0952-8180(03)00081-3
CrossRef
International Journal of Gynecology & Obstetrics
Management of breech presentation in areas with high prevalence of HIV infection
Holmes, WR; Hofmeyr, GJ
International Journal of Gynecology & Obstetrics, 87(3): 272-276.
10.1016/j.ijgo.2004.08.009
CrossRef
American Journal of Obstetrics and Gynecology
Approaches for scaling up human immunodeficiency virus testing and counseling in prevention of mother-to-child human immunodeficiency virus transmission settings in resource-limited countries
Bolu, OO; Allread, V; Creek, T; Stringer, E; Forna, F; Bulterys, M; Shaffer, N
American Journal of Obstetrics and Gynecology, 197(3): S83-S89.
10.1016/j.ajog.2007.03.006
CrossRef
Journal of Infectious Diseases
Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection
Supapol, WB; Remis, RS; Raboud, J; Millson, M; Tappero, J; Kaul, R; Kulkarni, P; McConnell, MS; Mock, PA; Culnane, M; McNicholl, J; Roongpisuthipong, A; Chotpitayasunondh, T; Shaffer, N; Butera, S
Journal of Infectious Diseases, 197(): 1369-1377.
10.1086/587488
CrossRef
International Journal of Std & AIDS
HIV-1 vertical transmission in Rio Grande, Southern Brazil
Tornatore, M; Goncalves, CV; Mendoza-Sassi, RA; Silveira, JM; D'avila, NE; Maas, CG; Bianchi, MS; Pinheiro, EM; Machado, ES; Soares, MA; Martinez, AMB
International Journal of Std & AIDS, 21(5): 351-355.
10.1258/ijsa.2009.009033
CrossRef
Frontiers in Bioscience
Animal models for perinatal transmission of HIV-1
Jayaraman, P; Haigwood, NL
Frontiers in Bioscience, 11(): 2828-2844.

Genes and Immunity
Gene-expression profiling of HIV-1 infection and perinatal transmission in Botswana
Montano, M; Rarick, M; Sebastiani, P; Brinkmann, P; Russell, M; Navis, A; Wester, C; Thior, I; Essex, M
Genes and Immunity, 7(4): 298-309.
10.1038/sj.gene.6364297
CrossRef
Reviews in Medical Virology
Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission
Lehman, DA; Farquhar, C
Reviews in Medical Virology, 17(6): 381-403.
10.1002/rmv.543
CrossRef
Journal of Infectious Diseases
Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand
Jourdain, G; Mary, JY; Le Coeur, S; Ngo-Giang-Huong, N; Yuthavisuthi, P; Limtrakul, A; Traisathit, P; McIntosh, K; Lallemant, M
Journal of Infectious Diseases, 196(): 1629-1636.
10.1086/522009
CrossRef
Archives of Pharmacal Research
Antiretroviral therapy 2006: Pharmacology, applications, and special situations
Samuel, R; Bettiker, R; Suh, B
Archives of Pharmacal Research, 29(6): 431-458.

Placenta
Vertical HIV-1 transmission: Prophylaxis and paediatric follow-up
Carneiro, M; Sanchez, A; Maneiro, P; Angelosante, W; Perez, C; Vallee, M
Placenta, 22(): S13-S18.
10.1053/plac.2001.0670
CrossRef
AIDS
Timing of mother-to-child transmission of HIV-1 and infant mortality in the first 6 months of life in Harare, Zimbabwe
Zijenah, LS; Moulton, LH; Iliff, P; Nathoo, K; Munjoma, MW; Mutasa, K; Malaba, L; Zvandasara, P; Ward, BJ; Humphrey, J; ZVITAMBO Study Group,
AIDS, 18(2): 273-280.

PDF (116)
AIDS
The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women
Meshnick, SR; Mwapasa, V; Rogerson, SJ; Molyneux, ME; Abrams, ET; Kamwendo, DD; Lema, VM; Tadesse, E; Chaluluka, E; Wilson, PE
AIDS, 18(7): 1051-1059.

PDF (117)
AIDS
The role of transplacental microtransfusions of maternal lymphocytes in HIV transmission to newborns
Biggar, RJ; Lee, T; Wen, L; Broadhead, R; Kumwenda, N; Taha, TE; Busch, MP
AIDS, 22(17): 2251-2256.
10.1097/QAD.0b013e328314e36b
PDF (125) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Risk Factors for In Utero and Intrapartum Transmission of HIV
Magder, LS; Mofenson, L; Paul, ME; Zorrilla, CD; Blattner, WA; Tuomala, RE; LaRussa, P; Landesman, S; Rich, KC
JAIDS Journal of Acquired Immune Deficiency Syndromes, 38(1): 87-95.

PDF (123)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Estimating the Net Effect of HIV on Child Mortality in African Populations Affected by Generalized HIV Epidemics
Marston, M; Zaba, B; Salomon, JA; Brahmbhatt, H; Bagenda, D
JAIDS Journal of Acquired Immune Deficiency Syndromes, 38(2): 219-227.

PDF (339)
JAIDS Journal of Acquired Immune Deficiency Syndromes
Population Attributable Fractions for Late Postnatal Mother-to-Child Transmission of HIV-1 in Sub-Saharan Africa
Goldenberg, RL; Read, JS; Chen, YQ; Young, A; Brown, ER; Chasela, CS; Fiscus, SA; Hoffman, IF; Valentine, M; Emel, L; Taha, TE
JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(3): 311-316.
10.1097/QAI.0b013e3181d61c2e
PDF (280) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Effectiveness of Short-Term and Long-Term Zidovudine Prophylaxis on Detection of HIV-1 Subtype E in Human Placenta and Vertical Transmission
Bhoopat, L; Khunamornpong, S; Lerdsrimongkol, P; Sirivatanapa, P; Sethavanich, S; Limtrakul, A; Gomutbuthra, V; Kajanavanich, S; Thorner, PS; Bhoopat, T
JAIDS Journal of Acquired Immune Deficiency Syndromes, 40(5): 545-550.

PDF (360)
Back to Top | Article Outline
Keywords:

Perinatal HIV transmission; timing; PCR; viral load; risk factors; Thailand

© 1999 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.